Genetic and physiological factors predisposing to individual selective serotonine reuptake inhibitors exposure during pregnancy and breast feeding

Anxiety and depression are very common during pregnancy. Post-partum period may frequently be complicated by more pro found due to hormonal changes, which lead fatal consequences for both — the mother child. The most commonly prescribed group of drugs ambulatory patient care is selective serotonine reuptake inhibitors (SSRIs). Absence clinical trials where pregnant or breast-feeding women were among participants has led situation when we can rule out effectiveness safety this drug class breastfeeding based only on real-life studies. Current know ledge let us conclude that all individual representatives have comparable efficacy profile. choice a single agent use difficult. In our paper analyzed genetic non-genetic factors, important pharmacokinetics various SSRIs in order reveal relevant each representative, determine those with stable pharmacokinetic parameters We also tried define theoretically clinically reliable safe fetus newborn. considered such factors as expected changes concentration periods pregnancy, probable impact pre-existing pharmacogenetic exposure, potential drug-drug interactions, current knowledge about extent distribution blood newborns